SII said it will be able to manufacture and supply 10 crore Covishield doses in June while also manufacturing Novavax.
Empty vials of Covishield, Serum Institute of India’s version of the AstraZeneca vaccine are seen on a table as people are inoculated against COVID-19 at a park in Srinagar, Indian controlled Kashmir, Tuesday, May 25, 2021. (AP Photo/ Dar Yasin)
The Serum Institute of India (SII) has applied to the Drug Controller General of India (DCGI) seeking permission to manufacture COVID-19
vaccine Sputnik V in the country, sources said on Thursday. The Pune-based firm has also sought approval for test analysis and examination. Russia’s Sputnik V vaccine is currently being manufactured in India by Dr Reddy’s Laboratories. “The Serum Institute of India (SII) put up an application to the Drugs Controller General of India (DCGI) on Wednesday seeking permission to manufacture the COVID-19 vaccine, Sputnik V, in India,” a source said.
The SII has already told the government that it will be able to manufacture and supply 10 crore Covishield doses in June, while it is also manufacturing the Novavax vaccine, the regulatory clearance for which is awaited from the United States.
The vaccine was given emergency use authorisation (EUA) by the DCGI in April.
A consignment of 30 lakh doses of Sputnik V landed in Hyderabad on Tuesday.
